Skip to main content

Table 3 Risk of colorectal cancer and molecular subgroups in relation to HRT and ERT use

From: Associations of hormone replacement therapy and oral contraceptives with risk of colorectal cancer defined by clinicopathological factors, beta-catenin alterations, expression of cyclin D1, p53, and microsatellite-instability

Tumour subgroups

HRT use

n

HR crude

p

HR adjusted

p

beta-catenin +

No

126

1.00

 

1.00

 

ERT

13

0.93(0.52-1.64)

0.790

1.04(0.58-1.84)

0.902

CHRT

19

0.64(0.40-1.04)

0.074

0.87(0.53-1.42)

0.868

beta-catenin −

No

80

1.00

 

1.00

 

ERT

7

0.76(0.35-1.65)

0.490

0.77(0.36-1.68)

0.516

CHRT

13

0.69(0.39-1.24)

0.217

0.83(0.46-1.50)

0.533

cyclin D1 +

No

173

1.00

 

1.00

 

ERT

16

0.81(0.49-1.35)

0.416

0.87(0.52-145)

0.591

CHRT

29

0.72(0.48-1.06)

0.096

0.93(0.63-1.39)

0.734

cyclin D1 −

No

31

1.00

 

1.00

 

ERT

4

1.16(0.41-3.28)

0.782

1.26(0.44-3.59)

0.661

CHRT

5

0.68(0.27-1.75)

0.425

0.84(0.32-2.19)

0.721

p53 +

No

99

1.00

 

1.00

 

ERT

11

0.98(0.53-1.83)

0.956

1.07(0.57-1.99)

0.843

CHRT

18

0.78(0.47-1.29)

0.334

1.00(0.59-1.65)

0.970

p53 −

No

107

1.00

 

1.00

 

ERT

9

0.74(0.37-1.45)

0.374

0.79(0.40-1.55)

0.488

CHRT

16

0.63(0.38-1.07)

0.089

0.84(0.49-1.42)

0.508

MSI

No

38

1.00

 

1.00

 

ERT

1

0.23(0.03-1.63)

0.140

0.24(0.03-1.72)

0.154

CHRT

5

0.56(0.22-1.43)

0.225

0.80(0.31-2.06)

0.649

MSS

No

164

1.00

 

1.00

 

ERT

18

0.97(0.60-1.58)

0.903

1.06(0.65-1.72)

0.829

CHRT

28

0.73(0.49-1.09)

0.120

0.92(0.61-1.39)

0.700

  1. Adjusted for age, bmi, educational level, smoking habits and alcohol consumption.